An Open-label Study of the Effect of First-line Herceptin Alone or in Combination With a Taxane on Tumor Response and Disease Progression in Patients With Metastatic Breast Cancer Who Relapsed After Receiving Adjuvant Herceptin for HER2-positive Early Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor response rate and progression
Event driven
No
Clinical Trials
Study Director
Hoffmann-La Roche
Australia: Ministry of Health
WO17299
NCT00475670
February 2005
September 2012
Name | Location |
---|